Fennec Pharmaceuticals (TSE:FRX) has released an update.
Fennec Pharmaceuticals has reported a solid second quarter in 2024 with total net revenues of $7.3 million and has welcomed Jeffrey S. Hackman as the new CEO and board member to drive future growth. The company boasts a strong financial position with approximately $43 million in cash and investments. Additionally, the firm is strengthening its market position for PEDMARK, aimed at preventing ototoxicity in young patients, following the recent update to the NCCN AYA Guidelines.
For further insights into TSE:FRX stock, check out TipRanks’ Stock Analysis page.
